{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T00:47:47Z","timestamp":1793234867739,"version":"4.5.0"},"reference-count":118,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,2,20]]},"DOI":"10.7759\/cureus.22419","type":"journal-article","created":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T07:48:56Z","timestamp":1645429736000},"source":"Crossref","is-referenced-by-count":24,"title":["Neuropathic Pain in Neurologic Disorders: A Narrative Review"],"prefix":"10.7759","author":[{"given":"Dimos-Dimitrios","family":"Mitsikostas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleni","family":"Moka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrique","family":"Orrillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Aurilio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athina","family":"Vadalouca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Paladini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giustino","family":"Varrassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1177\/2058738419838383","article-title":"The neuropathic pain: an overview of the current treatment and future therapeutic approaches","volume":"33","author":"Cavalli E","year":"2019","unstructured":"Cavalli E, Mammana S, Nicoletti F, Bramanti P, Mazzon E. The neuropathic pain: an overview of the current treatment and future therapeutic approaches. Int J Immunopathol Pharmacol. 2019, 33:2058738419838383. 10.1177\/2058738419838383","journal-title":"Int J Immunopathol Pharmacol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurol.2018.09.016","article-title":"Neuropathic pain: definition, assessment and epidemiology","volume":"175","author":"Bouhassira D","year":"2019","unstructured":"Bouhassira D. Neuropathic pain: definition, assessment and epidemiology. Rev Neurol (Paris). 2019, 175:16-25. 10.1016\/j.neurol.2018.09.016","journal-title":"Rev Neurol (Paris)"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1097\/WCO.0000000000000206","article-title":"Classification, diagnosis, and differential diagnosis of multiple sclerosis","volume":"28","author":"Katz Sand I","year":"2015","unstructured":"Katz Sand I. Classification, diagnosis, and differential diagnosis of multiple sclerosis. Curr Opin Neurol. 2015, 28:193-205. 10.1097\/WCO.0000000000000206","journal-title":"Curr Opin Neurol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2014.01.022","article-title":"The diagnosis of multiple sclerosis and the various related demyelinating syndromes: a critical review","volume":"48-49","author":"Karussis D","year":"2014","unstructured":"Karussis D. The diagnosis of multiple sclerosis and the various related demyelinating syndromes: a critical review. J Autoimmun. 2014, 48-49:134-42. 10.1016\/j.jaut.2014.01.022","journal-title":"J Autoimmun"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s00234-007-0216-2","article-title":"Idiopathic inflammatory-demyelinating diseases of the central nervous system","volume":"49","author":"Ca\u00f1ellas AR","year":"2007","unstructured":"Ca\u00f1ellas AR, Gols AR, Izquierdo JR, Subirana MT, Gairin XM. Idiopathic inflammatory-demyelinating diseases of the central nervous system. Neuroradiology. 2007, 49:393-409. 10.1007\/s00234-007-0216-2","journal-title":"Neuroradiology"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-0903-2","article-title":"Altered human oligodendrocyte heterogeneity in multiple sclerosis","volume":"566","author":"J\u00e4kel S","year":"2019","unstructured":"J\u00e4kel S, Agirre E, Mendanha Falc\u00e3o A, et al.. Altered human oligodendrocyte heterogeneity in multiple sclerosis. Nature. 2019, 566:543-7. 10.1038\/s41586-019-0903-2","journal-title":"Nature"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.cytogfr.2014.11.005","article-title":"IFN-\u03b2 and multiple sclerosis: cross-talking of immune cells and integration of immunoregulatory networks","volume":"26","author":"Severa M","year":"2015","unstructured":"Severa M, Rizzo F, Giacomini E, Salvetti M, Coccia EM. IFN-\u03b2 and multiple sclerosis: cross-talking of immune cells and integration of immunoregulatory networks. Cytokine Growth Factor Rev. 2015, 26:229-39. 10.1016\/j.cytogfr.2014.11.005","journal-title":"Cytokine Growth Factor Rev"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-cellbio-100913-013101","article-title":"Myelination of the nervous system: mechanisms and functions","volume":"30","author":"Nave KA","year":"2014","unstructured":"Nave KA, Werner HB. Myelination of the nervous system: mechanisms and functions. Annu Rev Cell Dev Biol. 2014, 30:503-33. 10.1146\/annurev-cellbio-100913-013101","journal-title":"Annu Rev Cell Dev Biol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-018-0842-3","article-title":"Dynamics of oligodendrocyte generation in multiple sclerosis","volume":"566","author":"Yeung MS","year":"2019","unstructured":"Yeung MS, Djelloul M, Steiner E, et al.. Dynamics of oligodendrocyte generation in multiple sclerosis. Nature. 2019, 566:538-42. 10.1038\/s41586-018-0842-3","journal-title":"Nature"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ncl.2016.06.016","article-title":"Epidemiology of multiple sclerosis","volume":"34","author":"Howard J","year":"2016","unstructured":"Howard J, Trevick S, Younger DS. Epidemiology of multiple sclerosis. Neurol Clin. 2016, 34:919-39. 10.1016\/j.ncl.2016.06.016","journal-title":"Neurol Clin"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurol.2015.10.006","article-title":"Epidemiology of multiple sclerosis","volume":"172","author":"Leray E","year":"2016","unstructured":"Leray E, Moreau T, Fromont A, Edan G. Epidemiology of multiple sclerosis. Rev Neurol (Paris). 2016, 172:3-13. 10.1016\/j.neurol.2015.10.006","journal-title":"Rev Neurol (Paris)"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000002469","article-title":"Multiple sclerosis prevalence in the United States commercially insured population","volume":"86","author":"Dilokthornsakul P","year":"2016","unstructured":"Dilokthornsakul P, Valuck RJ, Nair KV, Corboy JR, Allen RR, Campbell JD. Multiple sclerosis prevalence in the United States commercially insured population. Neurology. 2016, 86:1014-21. 10.1212\/WNL.0000000000002469","journal-title":"Neurology"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1111\/ane.13265","article-title":"Epidemiology of multiple sclerosis in Santiago de Compostela (Spain)","volume":"142","author":"Costa Arp\u00edn E","year":"2020","unstructured":"Costa Arp\u00edn E, Naveiro Soneira J, Lema Bouzas M, Gonz\u00e1lez Quintela A, Prieto Gonz\u00e1lez JM. Epidemiology of multiple sclerosis in Santiago de Compostela (Spain). Acta Neurol Scand. 2020, 142:267-74. 10.1111\/ane.13265","journal-title":"Acta Neurol Scand"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1111\/ane.13295","article-title":"Changes in multiple sclerosis epidemiology in Finland over five decades","volume":"142","author":"Pirttisalo AL","year":"2020","unstructured":"Pirttisalo AL, Soilu-H\u00e4nninen M, Sumelahti ML, et al.. Changes in multiple sclerosis epidemiology in Finland over five decades. Acta Neurol Scand. 2020, 142:200-9. 10.1111\/ane.13295","journal-title":"Acta Neurol Scand"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2011.09.003","article-title":"Why does the North-South gradient of incidence of multiple sclerosis seem to have disappeared on the northern hemisphere?","volume":"311","author":"Koch-Henriksen N","year":"2011","unstructured":"Koch-Henriksen N, Sorensen PS. Why does the North-South gradient of incidence of multiple sclerosis seem to have disappeared on the northern hemisphere?. J Neurol Sci. 2011, 311:58-63. 10.1016\/j.jns.2011.09.003","journal-title":"J Neurol Sci"},{"key":"ref16","unstructured":"Multiple Sclerosis News Today. MS statistics. multiple sclerosis news today; 2020 [updated March 5, 2020; cited 2021 December 1]. (2020). https:\/\/multiplesclerosisnewstoday.com\/multiple-sclerosis-overview\/statistics\/."},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)61620-7","article-title":"Multiple sclerosis","volume":"372","author":"Compston A","year":"2008","unstructured":"Compston A, Coles A. Multiple sclerosis. Lancet. 2008, 372:P1502-17. 10.1016\/S0140-6736(08)61620-7","journal-title":"Lancet"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000000560","article-title":"Defining the clinical course of multiple sclerosis: the 2013 revisions","volume":"83","author":"Lublin FD","year":"2014","unstructured":"Lublin FD, Reingold SC, Cohen JA, et al.. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology. 2014, 83:278-86. 10.1212\/WNL.0000000000000560","journal-title":"Neurology"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a028928","article-title":"Clinical course of multiple sclerosis","volume":"8","author":"Klineova S","year":"2018","unstructured":"Klineova S, Lublin FD. Clinical course of multiple sclerosis. Cold Spring Harb Perspect Med. 2018, 8:PMID: 29358317. 10.1101\/cshperspect.a028928","journal-title":"Cold Spring Harb Perspect Med"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(11)70274-5","article-title":"Clinically isolated syndromes","volume":"11","author":"Miller DH","year":"2012","unstructured":"Miller DH, Chard DT, Ciccarelli O. Clinically isolated syndromes. Lancet Neurol. 2012, 11:157-69. 10.1016\/S1474-4422(11)70274-5","journal-title":"Lancet Neurol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1007\/s11916-019-0800-2","article-title":"Advances in the understanding and management of chronic pain in multiple sclerosis: a comprehensive review","volume":"23","author":"Urits I","year":"2019","unstructured":"Urits I, Adamian L, Fiocchi J, et al.. Advances in the understanding and management of chronic pain in multiple sclerosis: a comprehensive review. Curr Pain Headache Rep. 2019, 23:59. 10.1007\/s11916-019-0800-2","journal-title":"Curr Pain Headache Rep"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2020.1757649","article-title":"An update on the pharmacological management of pain in patients with multiple sclerosis","volume":"21","author":"Chisari CG","year":"2020","unstructured":"Chisari CG, Sgarlata E, Arena S, D'Amico E, Toscano S, Patti F. An update on the pharmacological management of pain in patients with multiple sclerosis. Expert Opin Pharmacother. 2020, 21:2249-63. 10.1080\/14656566.2020.1757649","journal-title":"Expert Opin Pharmacother"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1007\/s11910-012-0320-5","article-title":"Pain and multiple sclerosis: pathophysiology and treatment","volume":"13","author":"Solaro C","year":"2013","unstructured":"Solaro C, Trabucco E, Messmer Uccelli M. Pain and multiple sclerosis: pathophysiology and treatment. Curr Neurol Neurosci Rep. 2013, 13:320. 10.1007\/s11910-012-0320-5","journal-title":"Curr Neurol Neurosci Rep"},{"key":"ref24","article-title":"Pain and MS","volume":"10","author":"Solaro C","year":"2003","unstructured":"Solaro C, Lunardi GL, Mancardi GL. Pain and MS. Int MS J. 2003, 10:14-9.","journal-title":"Int MS J"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2011.01962.x","article-title":"Headache in systemic lupus erythematosus vs multiple sclerosis: a prospective comparative study","volume":"51","author":"Katsiari CG","year":"2011","unstructured":"Katsiari CG, Vikelis M, Paraskevopoulou ES, Sfikakis PP, Mitsikostas DD. Headache in systemic lupus erythematosus vs multiple sclerosis: a prospective comparative study. Headache. 2011, 51:1398-407. 10.1111\/j.1526-4610.2011.01962.x","journal-title":"Headache"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-2982.2004.00790.x","article-title":"Prevalence of primary headaches in people with multiple sclerosis","volume":"24","author":"D'Amico D","year":"2004","unstructured":"D'Amico D, La Mantia L, Rigamonti A, et al.. Prevalence of primary headaches in people with multiple sclerosis. Cephalalgia. 2004, 24:980-4. 10.1111\/j.1468-2982.2004.00790.x","journal-title":"Cephalalgia"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.7224\/1537-2073.2012-035","article-title":"Headache in multiple sclerosis: features and implications for disease management","volume":"15","author":"Tabby D","year":"2013","unstructured":"Tabby D, Majeed MH, Youngman B, Wilcox J. Headache in multiple sclerosis: features and implications for disease management. Int J MS Care. 2013, 15:73-80. 10.7224\/1537-2073.2012-035","journal-title":"Int J MS Care"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1007\/s10194-010-0237-9","article-title":"Migraine is comorbid with multiple sclerosis and associated with a more symptomatic MS course","volume":"11","author":"Kister I","year":"2010","unstructured":"Kister I, Caminero AB, Monteith TS, et al.. Migraine is comorbid with multiple sclerosis and associated with a more symptomatic MS course. J Headache Pain. 2010, 11:417-25. 10.1007\/s10194-010-0237-9","journal-title":"J Headache Pain"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.46570\/utjms.2469-6706","article-title":"Migraine headache associated with multiple sclerosis: results from the nationwide inpatient sample","volume":"4","author":"Koffman B","year":"2021","unstructured":"Koffman B. Migraine headache associated with multiple sclerosis: results from the nationwide inpatient sample. Translation: The University of Toledo Journal of Medical Sciences. 2021, 4:1-5. 10.46570\/utjms.2469-6706","journal-title":"Translation: The University of Toledo Journal of Medical Sciences"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.101946","article-title":"Why do multiple sclerosis and migraine coexist?","volume":"40","author":"Hamamc\u0131 M","year":"2020","unstructured":"Hamamc\u0131 M, G\u00f6cmen AY, Say B, et al.. Why do multiple sclerosis and migraine coexist?. Mult Scler Relat Disord. 2020, 40:101946. 10.1016\/j.msard.2020.101946","journal-title":"Mult Scler Relat Disord"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1016\/j.jocn.2020.06.021","article-title":"The prevalence of migraine in multiple sclerosis (MS): a systematic review and meta-analysis","volume":"79","author":"Mirmosayyeb O","year":"2020","unstructured":"Mirmosayyeb O, Barzegar M, Nehzat N, Shaygannejad V, Sahraian MA, Ghajarzadeh M. The prevalence of migraine in multiple sclerosis (MS): a systematic review and meta-analysis. J Clin Neurosci. 2020, 79:33-8. 10.1016\/j.jocn.2020.06.021","journal-title":"J Clin Neurosci"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2012.10.003","article-title":"Migraine and multiple sclerosis: epidemiology and approach to treatment","volume":"2","author":"Gelfand AA","year":"2013","unstructured":"Gelfand AA, Gelfand JM, Goadsby PJ. Migraine and multiple sclerosis: epidemiology and approach to treatment. Mult Scler Relat Disord. 2013, 2:73-9. 10.1016\/j.msard.2012.10.003","journal-title":"Mult Scler Relat Disord"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-021-01233-7","article-title":"21st century headache: mapping new territory","volume":"22","author":"Goadsby PJ","year":"2021","unstructured":"Goadsby PJ, Lant\u00e9ri-Minet M, Michel MC, et al.. 21st century headache: mapping new territory. J Headache Pain. 2021, 22:19. 10.1186\/s10194-021-01233-7","journal-title":"J Headache Pain"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012622.pub2","article-title":"Non-pharmacological interventions for chronic pain in multiple sclerosis","volume":"12","author":"Amatya B","year":"2018","unstructured":"Amatya B, Young J, Khan F. Non-pharmacological interventions for chronic pain in multiple sclerosis. Cochrane Database Syst Rev. 2018, 12:CD012622. 10.1002\/14651858.CD012622.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"ref35","article-title":"Influence of yoga and aerobics exercise on fatigue, pain and psychosocial status in patients with multiple sclerosis: a randomized trial","volume":"56","author":"Hasanpour Dehkordi A","year":"2016","unstructured":"Hasanpour Dehkordi A. Influence of yoga and aerobics exercise on fatigue, pain and psychosocial status in patients with multiple sclerosis: a randomized trial. J Sports Med Phys Fitness. 2016, 56:1417-22.","journal-title":"J Sports Med Phys Fitness"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-017-0960-9","article-title":"Exercise prescription for patients with multiple sclerosis: potential benefits and practical recommendations","volume":"17","author":"Halabchi F","year":"2017","unstructured":"Halabchi F, Alizadeh Z, Sahraian MA, Abolhasani M. Exercise prescription for patients with multiple sclerosis: potential benefits and practical recommendations. BMC Neurol. 2017, 17:185. 10.1186\/s12883-017-0960-9","journal-title":"BMC Neurol"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1007\/s11910-019-0991-2","article-title":"Assessment and measurement of spasticity in MS: state of the evidence","volume":"19","author":"Hugos CL","year":"2019","unstructured":"Hugos CL, Cameron MH. Assessment and measurement of spasticity in MS: state of the evidence. Curr Neurol Neurosci Rep. 2019, 19:79. 10.1007\/s11910-019-0991-2","journal-title":"Curr Neurol Neurosci Rep"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1177\/1352458520970841","article-title":"Rising prevalence of multiple sclerosis worldwide: insights from the atlas of MS, third edition","volume":"26","author":"Walton C","year":"2020","unstructured":"Walton C, King R, Rechtman L, et al.. Rising prevalence of multiple sclerosis worldwide: insights from the atlas of MS, third edition. Mult Scler. 2020, 26:1816-21. 10.1177\/1352458520970841","journal-title":"Mult Scler"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1007\/s11916-011-0181-7","article-title":"Diagnosis and treatment of pain in small-fiber neuropathy","volume":"15","author":"Hovaguimian A","year":"2011","unstructured":"Hovaguimian A, Gibbons CH. Diagnosis and treatment of pain in small-fiber neuropathy. Curr Pain Headache Rep. 2011, 15:193-200. 10.1007\/s11916-011-0181-7","journal-title":"Curr Pain Headache Rep"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.13611","article-title":"Distal symmetric polyneuropathy: a review","volume":"314","author":"Callaghan BC","year":"2015","unstructured":"Callaghan BC, Price RS, Feldman EL. Distal symmetric polyneuropathy: a review. JAMA. 2015, 314:2172-81. 10.1001\/jama.2015.13611","journal-title":"JAMA"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1007\/s40122-020-00210-3","article-title":"Pharmacological management of painful peripheral neuropathies: a systematic review","volume":"10","author":"Liampas A","year":"2021","unstructured":"Liampas A, Rekatsina M, Vadalouca A, Paladini A, Varrassi G, Zis P. Pharmacological management of painful peripheral neuropathies: a systematic review. Pain Ther. 2021, 10:55-68. 10.1007\/s40122-020-00210-3","journal-title":"Pain Ther"},{"key":"ref42","article-title":"Peripheral neuropathy","author":"Mayo Clinic","year":"2019","unstructured":"Mayo Clinic. Peripheral neuropathy. Mayo Clinic, Rochester, Minnesota. 2019, Accessed: November 19. Available from: https:\/\/www.mayoclinic.org\/diseases-conditions\/peripheral-neuropathy\/symptoms-causes\/syc-20352061."},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1016\/j.mcna.2018.10.006","article-title":"Peripheral neuropathy","volume":"103","author":"Barrell K","year":"2019","unstructured":"Barrell K, Smith AG. Peripheral neuropathy. Med Clin North Am. 2019, 103:383-97. 10.1016\/j.mcna.2018.10.006","journal-title":"Med Clin North Am"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.62.4.310","article-title":"Epidemiology of peripheral neuropathy","volume":"62","author":"Martyn CN","year":"1997","unstructured":"Martyn CN, Hughes RA. Epidemiology of peripheral neuropathy. J Neurol Neurosurg Psychiatry. 1997, 62:310-8. 10.1136\/jnnp.62.4.310","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref45","article-title":"Chronic symmetric symptomatic polyneuropathy in the elderly: a field screening investigation in two Italian regions. I. Prevalence and general characteristics of the sample","volume":"45","author":"Italian General Practitioner Study Group (IGPSG)","year":"1995","unstructured":"Italian General Practitioner Study Group (IGPSG). Chronic symmetric symptomatic polyneuropathy in the elderly: a field screening investigation in two Italian regions. I. Prevalence and general characteristics of the sample. Neurology. 1995, 45:1832-6.","journal-title":"Neurology"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2020.03.025","article-title":"Central obesity is associated with neuropathy in the severely obese","volume":"95","author":"Callaghan BC","year":"2020","unstructured":"Callaghan BC, Reynolds E, Banerjee M, Chant E, Villegas-Umana E, Feldman EL. Central obesity is associated with neuropathy in the severely obese. Mayo Clin Proc. 2020, 95:1342-53. 10.1016\/j.mayocp.2020.03.025","journal-title":"Mayo Clin Proc"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2015.05.004","article-title":"Peripheral neuropathy: a practical approach to diagnosis and symptom management","volume":"90","author":"Watson JC","year":"2015","unstructured":"Watson JC, Dyck PJ. Peripheral neuropathy: a practical approach to diagnosis and symptom management. Mayo Clin Proc. 2015, 90:940-51. 10.1016\/j.mayocp.2015.05.004","journal-title":"Mayo Clin Proc"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000336370.51010.a1","article-title":"Practice parameter: evaluation of distal symmetric polyneuropathy: role of laboratory and genetic testing (an evidence-based review). Report of the American Academy of Neurology, American Association of Neuromuscular and Electrodiagnostic Medicine, and American Academy of Physical Medicine and Rehabilitation","volume":"72","author":"England JD","year":"2009","unstructured":"England JD, Gronseth GS, Franklin G, et al.. Practice parameter: evaluation of distal symmetric polyneuropathy: role of laboratory and genetic testing (an evidence-based review). Report of the American Academy of Neurology, American Association of Neuromuscular and Electrodiagnostic Medicine, and American Academy of Physical Medicine and Rehabilitation. Neurology. 2009, 72:185-92. 10.1212\/01.wnl.0000336370.51010.a1","journal-title":"Neurology"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.2174\/1574884714666190121154813","article-title":"Drug-induced peripheral neuropathy: a narrative review","volume":"15","author":"Jones MR","year":"2020","unstructured":"Jones MR, Urits I, Wolf J, et al.. Drug-induced peripheral neuropathy: a narrative review. Curr Clin Pharmacol. 2020, 15:38-48. 10.2174\/1574884714666190121154813","journal-title":"Curr Clin Pharmacol"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/2091960","article-title":"Quality of life in painful peripheral neuropathies: a systematic review","volume":"2019","author":"Girach A","year":"2019","unstructured":"Girach A, Julian TH, Varrassi G, Paladini A, Vadalouka A, Zis P. Quality of life in painful peripheral neuropathies: a systematic review. Pain Res Manag. 2019, 2019:2091960. 10.1155\/2019\/2091960","journal-title":"Pain Res Manag"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.3390\/nu10060662","article-title":"Quality of life in patients with gluten neuropathy: a case-controlled study","volume":"10","author":"Zis P","year":"2018","unstructured":"Zis P, Sarrigiannis PG, Rao DG, Hadjivassiliou M. Quality of life in patients with gluten neuropathy: a case-controlled study. Nutrients. 2018, 10:10.3390\/nu10060662","journal-title":"Nutrients"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(09)70290-X","article-title":"Gluten sensitivity: from gut to brain","volume":"9","author":"Hadjivassiliou M","year":"2010","unstructured":"Hadjivassiliou M, Sanders DS, Gr\u00fcnewald RA, et al.. Gluten sensitivity: from gut to brain. Lancet Neurol. 2010, 9:318-30. 10.1016\/S1474-4422(09)70290-X","journal-title":"Lancet Neurol"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-018-8978-5","article-title":"Gluten neuropathy: prevalence of neuropathic pain and the role of gluten-free diet","volume":"265","author":"Zis P","year":"2018","unstructured":"Zis P, Sarrigiannis PG, Rao DG, Hadjivassiliou M. Gluten neuropathy: prevalence of neuropathic pain and the role of gluten-free diet. J Neurol. 2018, 265:2231-6. 10.1007\/s00415-018-8978-5","journal-title":"J Neurol"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1016\/j.neulet.2018.11.054","article-title":"The multiple challenges of neuropathic pain","volume":"702","author":"Bouhassira D","year":"2019","unstructured":"Bouhassira D, Attal N. The multiple challenges of neuropathic pain. Neurosci Lett. 2019, 702:6-10. 10.1016\/j.neulet.2018.11.054","journal-title":"Neurosci Lett"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000282763.29778.59","article-title":"Neuropathic pain: redefinition and a grading system for clinical and research purposes","volume":"70","author":"Treede RD","year":"2008","unstructured":"Treede RD, Jensen TS, Campbell JN, et al.. Neuropathic pain: redefinition and a grading system for clinical and research purposes. Neurology. 2008, 70:1630-5. 10.1212\/01.wnl.0000282763.29778.59","journal-title":"Neurology"},{"key":"ref56","article-title":"IASP terminology","author":"International Association for the Study of Pain","year":"2020","unstructured":"International Association for the Study of Pain. IASP terminology. International Association for the Study of Pain. 2020, Accessed: September 10. Available from: https:\/\/www.iasp-pain.org\/Education\/Content.aspx."},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1097\/j.pain.0000000000001365","article-title":"The IASP classification of chronic pain for ICD-11: chronic neuropathic pain","volume":"160","author":"Scholz J","year":"2019","unstructured":"Scholz J, Finnerup NB, Attal N, et al.. The IASP classification of chronic pain for ICD-11: chronic neuropathic pain. Pain. 2019, 160:53-9. 10.1097\/j.pain.0000000000001365","journal-title":"Pain"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1080\/01658107.2018.1523932","article-title":"Herpes zoster oticus, ophthalmicus, and cutaneous disseminated: case report and literature review","volume":"43","author":"Pitton Rissardo J","year":"2019","unstructured":"Pitton Rissardo J, Fornari Caprara AL. Herpes zoster oticus, ophthalmicus, and cutaneous disseminated: case report and literature review. Neuroophthalmology. 2019, 43:407-10. 10.1080\/01658107.2018.1523932","journal-title":"Neuroophthalmology"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2017.2","article-title":"Neuropathic pain","volume":"3","author":"Colloca L","year":"2017","unstructured":"Colloca L, Ludman T, Bouhassira D, et al.. Neuropathic pain. Nat Rev Dis Primers. 2017, 3:17002. 10.1038\/nrdp.2017.2","journal-title":"Nat Rev Dis Primers"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00045.2019","article-title":"Neuropathic pain: from mechanisms to treatment","volume":"101","author":"Finnerup NB","year":"2021","unstructured":"Finnerup NB, Kuner R, Jensen TS. Neuropathic pain: from mechanisms to treatment. Physiol Rev. 2021, 101:259-301. 10.1152\/physrev.00045.2019","journal-title":"Physiol Rev"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpain.2005.11.008","article-title":"The epidemiology of chronic pain of predominantly neuropathic origin. Results from a general population survey","volume":"7","author":"Torrance N","year":"2006","unstructured":"Torrance N, Smith BH, Bennett MI, Lee AJ. The epidemiology of chronic pain of predominantly neuropathic origin. Results from a general population survey. J Pain. 2006, 7:281-9. 10.1016\/j.jpain.2005.11.008","journal-title":"J Pain"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2007.08.013","article-title":"Prevalence of chronic pain with neuropathic characteristics in the general population","volume":"136","author":"Bouhassira D","year":"2008","unstructured":"Bouhassira D, Lant\u00e9ri-Minet M, Attal N, Laurent B, Touboul C. Prevalence of chronic pain with neuropathic characteristics in the general population. Pain. 2008, 136:380-7. 10.1016\/j.pain.2007.08.013","journal-title":"Pain"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2013.11.013","article-title":"Neuropathic pain in the general population: a systematic review of epidemiological studies","volume":"155","author":"van Hecke O","year":"2014","unstructured":"van Hecke O, Austin SK, Khan RA, Smith BH, Torrance N. Neuropathic pain in the general population: a systematic review of epidemiological studies. Pain. 2014, 155:654-62. 10.1016\/j.pain.2013.11.013","journal-title":"Pain"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.2147\/CEOR.S81396","article-title":"A burden of illness study for neuropathic pain in Europe","volume":"8","author":"Liedgens H","year":"2016","unstructured":"Liedgens H, Obradovic M, De Courcy J, Holbrook T, Jakubanis R. A burden of illness study for neuropathic pain in Europe. Clinicoecon Outcomes Res. 2016, 8:113-26. 10.2147\/CEOR.S81396","journal-title":"Clinicoecon Outcomes Res"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.1007\/s40122-017-0087-0","article-title":"A review of neuropathic pain: from guidelines to clinical practice","volume":"6","author":"Cruccu G","year":"2017","unstructured":"Cruccu G, Truini A. A review of neuropathic pain: from guidelines to clinical practice. Pain Ther. 2017, 6:35-42. 10.1007\/s40122-017-0087-0","journal-title":"Pain Ther"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(14)70251-0","article-title":"Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis","volume":"14","author":"Finnerup NB","year":"2015","unstructured":"Finnerup NB, Attal N, Haroutounian S, et al.. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol. 2015, 14:162-73. 10.1016\/S1474-4422(14)70251-0","journal-title":"Lancet Neurol"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2013.06.004","article-title":"Interventional management of neuropathic pain: NeuPSIG recommendations","volume":"154","author":"Dworkin RH","year":"2013","unstructured":"Dworkin RH, O'Connor AB, Kent J, et al.. Interventional management of neuropathic pain: NeuPSIG recommendations. Pain. 2013, 154:2249-61. 10.1016\/j.pain.2013.06.004","journal-title":"Pain"},{"key":"ref68","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2010.07.031","article-title":"NeuPSIG guidelines on neuropathic pain assessment","volume":"152","author":"Haanp\u00e4\u00e4 M","year":"2011","unstructured":"Haanp\u00e4\u00e4 M, Attal N, Backonja M, et al.. NeuPSIG guidelines on neuropathic pain assessment. Pain. 2011, 152:14-27. 10.1016\/j.pain.2010.07.031","journal-title":"Pain"},{"key":"ref69","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2010.02999.x","article-title":"EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision","volume":"17","author":"Attal N","year":"2010","unstructured":"Attal N, Cruccu G, Baron R, et al.. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol. 2010, 17:1113-e88. 10.1111\/j.1468-1331.2010.02999.x","journal-title":"Eur J Neurol"},{"key":"ref70","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2010.02969.x","article-title":"EFNS guidelines on neuropathic pain assessment: revised 2009","volume":"17","author":"Cruccu G","year":"2010","unstructured":"Cruccu G, Sommer C, Anand P, et al.. EFNS guidelines on neuropathic pain assessment: revised 2009. Eur J Neurol. 2010, 17:1010-8. 10.1111\/j.1468-1331.2010.02969.x","journal-title":"Eur J Neurol"},{"key":"ref71","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2007.01916.x","article-title":"EFNS guidelines on neurostimulation therapy for neuropathic pain","volume":"14","author":"Cruccu G","year":"2007","unstructured":"Cruccu G, Aziz TZ, Garcia-Larrea L, et al.. EFNS guidelines on neurostimulation therapy for neuropathic pain. Eur J Neurol. 2007, 14:952-70. 10.1111\/j.1468-1331.2007.01916.x","journal-title":"Eur J Neurol"},{"key":"ref72","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/794325","article-title":"Evidence-based guideline for neuropathic pain interventional treatments: spinal cord stimulation, intravenous infusions, epidural injections and nerve blocks","volume":"17","author":"Mailis A","year":"2012","unstructured":"Mailis A, Taenzer P. Evidence-based guideline for neuropathic pain interventional treatments: spinal cord stimulation, intravenous infusions, epidural injections and nerve blocks. Pain Res Manag. 2012, 17:150-8. 10.1155\/2012\/794325","journal-title":"Pain Res Manag"},{"key":"ref73","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/754693","article-title":"Pharmacological management of chronic neuropathic pain: revised consensus statement from the Canadian Pain Society","volume":"19","author":"Moulin D","year":"2014","unstructured":"Moulin D, Boulanger A, Clark AJ, et al.. Pharmacological management of chronic neuropathic pain: revised consensus statement from the Canadian Pain Society. Pain Res Manag. 2014, 19:328-35. 10.1155\/2014\/754693","journal-title":"Pain Res Manag"},{"key":"ref74","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4637.2004.04019.x","article-title":"Comorbidities in chronic neuropathic pain","volume":"5(Suppl 1)","author":"Nicholson B","year":"2004","unstructured":"Nicholson B, Verma S. Comorbidities in chronic neuropathic pain. Pain Med. 2004, 5(Suppl 1):S9-S27. 10.1111\/j.1526-4637.2004.04019.x","journal-title":"Pain Med"},{"key":"ref75","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000259085.61898.9e","article-title":"The impact of neuropathic pain on health-related quality of life: review and implications","volume":"68","author":"Jensen MP","year":"2007","unstructured":"Jensen MP, Chodroff MJ, Dworkin RH. The impact of neuropathic pain on health-related quality of life: review and implications. Neurology. 2007, 68:1178-82. 10.1212\/01.wnl.0000259085.61898.9e","journal-title":"Neurology"},{"key":"ref76","doi-asserted-by":"publisher","DOI":"10.1007\/s11916-012-0256-0","article-title":"Epidemiology of neuropathic pain and its impact on quality of life","volume":"16","author":"Smith BH","year":"2012","unstructured":"Smith BH, Torrance N. Epidemiology of neuropathic pain and its impact on quality of life. Curr Pain Headache Rep. 2012, 16:191-8. 10.1007\/s11916-012-0256-0","journal-title":"Curr Pain Headache Rep"},{"key":"ref77","doi-asserted-by":"publisher","DOI":"10.2217\/pmt-2020-0098","article-title":"Unmet needs in the management of functional impairment in patients with chronic pain: a multinational survey","volume":"11","author":"Karra R","year":"2021","unstructured":"Karra R, Holten-Rossing S, Mohammed D, Parmeggiani L, Heine M, Namn\u00fan OC. Unmet needs in the management of functional impairment in patients with chronic pain: a multinational survey. Pain Manag. 2021, 11:303-14. 10.2217\/pmt-2020-0098","journal-title":"Pain Manag"},{"key":"ref78","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2009.04.006","article-title":"Assessment of neuropathic pain in primary care","volume":"122","author":"Haanp\u00e4\u00e4 ML","year":"2009","unstructured":"Haanp\u00e4\u00e4 ML, Backonja MM, Bennett MI, et al.. Assessment of neuropathic pain in primary care. Am J Med. 2009, 122:S13-S21. 10.1016\/j.amjmed.2009.04.006","journal-title":"Am J Med"},{"key":"ref79","doi-asserted-by":"publisher","DOI":"10.1186\/s12871-015-0150-5","article-title":"Clinical practice guidelines for the management of neuropathic pain: a systematic review","volume":"16","author":"Deng Y","year":"2016","unstructured":"Deng Y, Luo L, Hu Y, Fang K, Liu J. Clinical practice guidelines for the management of neuropathic pain: a systematic review. BMC Anesthesiol. 2016, 16:12. 10.1186\/s12871-015-0150-5","journal-title":"BMC Anesthesiol"},{"key":"ref80","doi-asserted-by":"publisher","DOI":"10.1093\/pm\/pnz075","article-title":"A comprehensive algorithm for management of neuropathic pain","volume":"20","author":"Bates D","year":"2019","unstructured":"Bates D, Schultheis BC, Hanes MC, et al.. A comprehensive algorithm for management of neuropathic pain. Pain Med. 2019, 20:S2-S12. 10.1093\/pm\/pnz075","journal-title":"Pain Med"},{"key":"ref81","doi-asserted-by":"publisher","DOI":"10.1196\/annals.1366.016","article-title":"Therapeutic management of chronic neuropathic pain: an examination of pharmacologic treatment","volume":"1088","author":"Vadalouca A","year":"2006","unstructured":"Vadalouca A, Siafaka I, Argyra E, Vrachnou E, Moka E. Therapeutic management of chronic neuropathic pain: an examination of pharmacologic treatment. Ann N Y Acad Sci. 2006, 1088:164-86. 10.1196\/annals.1366.016","journal-title":"Ann N Y Acad Sci"},{"key":"ref82","doi-asserted-by":"publisher","DOI":"10.1111\/j.1533-2500.2011.00485.x","article-title":"Pharmacological treatment of neuropathic cancer pain: a comprehensive review of the current literature","volume":"12","author":"Vadalouca A","year":"2012","unstructured":"Vadalouca A, Raptis E, Moka E, Zis P, Sykioti P, Siafaka I. Pharmacological treatment of neuropathic cancer pain: a comprehensive review of the current literature. Pain Pract. 2012, 12:219-51. 10.1111\/j.1533-2500.2011.00485.x","journal-title":"Pain Pract"},{"key":"ref83","doi-asserted-by":"publisher","DOI":"10.2174\/138161209788186272","article-title":"Neuropathic pain: models and mechanisms","volume":"15","author":"Jarvis MF","year":"2009","unstructured":"Jarvis MF, Boyce-Rustay JM. Neuropathic pain: models and mechanisms. Curr Pharm Des. 2009, 15:1711-6. 10.2174\/138161209788186272","journal-title":"Curr Pharm Des"},{"key":"ref84","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2011.619431","article-title":"The relevance of neuropathic components in chronic back pain","volume":"27","author":"Morlion B","year":"2011","unstructured":"Morlion B. The relevance of neuropathic components in chronic back pain. Curr Med Res Opin. 2011, 27:2067-8. 10.1185\/03007995.2011.619431","journal-title":"Curr Med Res Opin"},{"key":"ref85","doi-asserted-by":"publisher","DOI":"10.3390\/toxins9090260","article-title":"Botulinum toxin for the treatment of neuropathic pain","volume":"9","author":"Park J","year":"2017","unstructured":"Park J, Park HJ. Botulinum toxin for the treatment of neuropathic pain. Toxins (Basel). 2017, 9:10.3390\/toxins9090260","journal-title":"Toxins (Basel)"},{"key":"ref86","doi-asserted-by":"publisher","DOI":"10.1016\/j.toxicon.2018.01.017","article-title":"Botulinum toxin treatment of pain syndromes: an evidence based review","volume":"147","author":"Safarpour Y","year":"2018","unstructured":"Safarpour Y, Jabbari B. Botulinum toxin treatment of pain syndromes: an evidence based review. Toxicon. 2018, 147:120-8. 10.1016\/j.toxicon.2018.01.017","journal-title":"Toxicon"},{"key":"ref87","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2007.12.002","article-title":"Duloxetine for the management of diabetic peripheral neuropathic pain: evidence-based findings from post hoc analysis of three multicenter, randomized, double-blind, placebo-controlled, parallel-group studies","volume":"29(Suppl)","author":"Kajdasz DK","year":"2007","unstructured":"Kajdasz DK, Iyengar S, Desaiah D, et al.. Duloxetine for the management of diabetic peripheral neuropathic pain: evidence-based findings from post hoc analysis of three multicenter, randomized, double-blind, placebo-controlled, parallel-group studies. Clin Ther. 2007, 29(Suppl):2536-46. 10.1016\/j.clinthera.2007.12.002","journal-title":"Clin Ther"},{"key":"ref88","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpain.2008.03.012","article-title":"Summary measures of number needed to treat: how much clinical guidance do they provide in neuropathic pain?","volume":"13","author":"Edelsberg J","year":"2009","unstructured":"Edelsberg J, Oster G. Summary measures of number needed to treat: how much clinical guidance do they provide in neuropathic pain?. Eur J Pain. 2009, 13:11-6. 10.1016\/j.ejpain.2008.03.012","journal-title":"Eur J Pain"},{"key":"ref89","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2017.1310092","article-title":"Multimodal analgesia in moderate-to-severe pain: a role for a new fixed combination of dexketoprofen and tramadol","volume":"33","author":"Varrassi G","year":"2017","unstructured":"Varrassi G, Hanna M, Macheras G, et al.. Multimodal analgesia in moderate-to-severe pain: a role for a new fixed combination of dexketoprofen and tramadol. Curr Med Res Opin. 2017, 33:1165-73. 10.1080\/03007995.2017.1310092","journal-title":"Curr Med Res Opin"},{"key":"ref90","article-title":"Rationale for the use of adjuvants in acute pain","volume":"57","author":"Varrassi G","year":"1991","unstructured":"Varrassi G, De Nicola A. Rationale for the use of adjuvants in acute pain. Minerva Anestesiol. 1991, 57:1271-4.","journal-title":"Minerva Anestesiol"},{"key":"ref91","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10163533","article-title":"Combination therapy for neuropathic pain: a review of recent evidence","volume":"10","author":"Serrano Afonso A","year":"2021","unstructured":"Serrano Afonso A, Carnaval T, Videla C\u00e9s S. Combination therapy for neuropathic pain: a review of recent evidence. J Clin Med. 2021, 10:10.3390\/jcm10163533","journal-title":"J Clin Med"},{"key":"ref92","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008943.pub2","article-title":"Combination pharmacotherapy for the treatment of neuropathic pain in adults","volume":"2012","author":"Chaparro LE","year":"2012","unstructured":"Chaparro LE, Wiffen PJ, Moore RA, Gilron I. Combination pharmacotherapy for the treatment of neuropathic pain in adults. Cochrane Database Syst Rev. 2012, 2012:CD008943. 10.1002\/14651858.CD008943.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"ref93","doi-asserted-by":"publisher","DOI":"10.1097\/j.pain.0000000000000149","article-title":"Combination of morphine with nortriptyline for neuropathic pain","volume":"156","author":"Gilron I","year":"2015","unstructured":"Gilron I, Tu D, Holden RR, Jackson AC, DuMerton-Shore D. Combination of morphine with nortriptyline for neuropathic pain. Pain. 2015, 156:1440-8. 10.1097\/j.pain.0000000000000149","journal-title":"Pain"},{"key":"ref94","doi-asserted-by":"publisher","DOI":"10.2147\/JPR.S138099","article-title":"Combination treatment of neuropathic pain: Danish expert recommendations based on a Delphi process","volume":"10","author":"Holbech JV","year":"2017","unstructured":"Holbech JV, Jung A, Jonsson T, Wanning M, Bredahl C, Bach FW. Combination treatment of neuropathic pain: Danish expert recommendations based on a Delphi process. J Pain Res. 2017, 10:1467-75. 10.2147\/JPR.S138099","journal-title":"J Pain Res"},{"key":"ref95","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010692.pub3","article-title":"Oxycodone for neuropathic pain in adults","volume":"7","author":"Gaskell H","year":"2016","unstructured":"Gaskell H, Derry S, Stannard C, Moore RA. Oxycodone for neuropathic pain in adults. Cochrane Database Syst Rev. 2016, 7:CD010692. 10.1002\/14651858.CD010692.pub3","journal-title":"Cochrane Database Syst Rev"},{"key":"ref96","doi-asserted-by":"publisher","DOI":"10.1007\/s40122-018-0095-8","article-title":"Tapentadol extended release in the treatment of severe chronic low back pain and osteoarthritis pain","volume":"7","author":"Pergolizzi JV Jr","year":"2018","unstructured":"Pergolizzi JV Jr, Taylor R Jr, LeQuang JA, Raffa RB, Bisney J. Tapentadol extended release in the treatment of severe chronic low back pain and osteoarthritis pain. Pain Ther. 2018, 7:37-57. 10.1007\/s40122-018-0095-8","journal-title":"Pain Ther"},{"key":"ref97","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007963.pub3","article-title":"Oxcarbazepine for neuropathic pain","volume":"12","author":"Zhou M","year":"2017","unstructured":"Zhou M, Chen N, He L, Yang M, Zhu C, Wu F. Oxcarbazepine for neuropathic pain. Cochrane Database Syst Rev. 2017, 12:CD007963. 10.1002\/14651858.CD007963.pub3","journal-title":"Cochrane Database Syst Rev"},{"key":"ref98","doi-asserted-by":"publisher","DOI":"10.1007\/s11916-018-0658-8","article-title":"Medical cannabis for neuropathic pain","volume":"22","author":"Lee G","year":"2018","unstructured":"Lee G, Grovey B, Furnish T, Wallace M. Medical cannabis for neuropathic pain. Curr Pain Headache Rep. 2018, 22:8. 10.1007\/s11916-018-0658-8","journal-title":"Curr Pain Headache Rep"},{"key":"ref99","doi-asserted-by":"publisher","DOI":"10.1016\/S0025-6196(11)61475-4","article-title":"Consensus guidelines: treatment planning and options. Diabetic peripheral neuropathic pain","volume":"81","author":"Argoff CE","year":"2006","unstructured":"Argoff CE, Backonja MM, Belgrade MJ, et al.. Consensus guidelines: treatment planning and options. Diabetic peripheral neuropathic pain. Mayo Clin Proc. 2006, 81:12-25. 10.1016\/S0025-6196(11)61475-4","journal-title":"Mayo Clin Proc"},{"key":"ref100","doi-asserted-by":"publisher","DOI":"10.1097\/PR9.0000000000000884","article-title":"Potential for increased prevalence of neuropathic pain after the COVID-19 pandemic","volume":"6","author":"Attal N","year":"2021","unstructured":"Attal N, Martinez V, Bouhassira D. Potential for increased prevalence of neuropathic pain after the COVID-19 pandemic. Pain Rep. 2021, 6:e884. 10.1097\/PR9.0000000000000884","journal-title":"Pain Rep"},{"key":"ref101","doi-asserted-by":"publisher","DOI":"10.22514\/sv.2021.067","article-title":"It's not over till it's over: a narrative review of Long COVID","volume":"17","author":"Pergolizzi J","year":"2021","unstructured":"Pergolizzi J, LeQuang J, Magnusson P, et al.. It's not over till it's over: a narrative review of Long COVID. Signa Vitae. 2021, 17:21-30. 10.22514\/sv.2021.067","journal-title":"Signa Vitae"},{"key":"ref102","doi-asserted-by":"publisher","DOI":"10.1126\/science.abd2985","article-title":"Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity","volume":"370","author":"Cantuti-Castelvetri L","year":"2020","unstructured":"Cantuti-Castelvetri L, Ojha R, Pedro LD, et al.. Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity. Science. 2020, 370:856-60. 10.1126\/science.abd2985","journal-title":"Science"},{"key":"ref103","doi-asserted-by":"publisher","DOI":"10.1080\/00325481.2020.1837503","article-title":"Potential neurological manifestations of COVID-19: a narrative review","volume":"[Epub ahead of print]","author":"Pergolizzi JV Jr","year":"2021","unstructured":"Pergolizzi JV Jr, Raffa RB, Varrassi G, et al.. Potential neurological manifestations of COVID-19: a narrative review. Postgrad Med. 2021, [Epub ahead of print]:1-11. 10.1080\/00325481.2020.1837503","journal-title":"Postgrad Med"},{"key":"ref104","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(10)70143-5","article-title":"Neuropathic pain: diagnosis, pathophysiological mechanisms, and treatment","volume":"9","author":"Baron R","year":"2010","unstructured":"Baron R, Binder A, Wasner G. Neuropathic pain: diagnosis, pathophysiological mechanisms, and treatment. Lancet Neurol. 2010, 9:807-19. 10.1016\/S1474-4422(10)70143-5","journal-title":"Lancet Neurol"},{"key":"ref105","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.060146","article-title":"Neuropathic pain: a practical guide for the clinician","volume":"175","author":"Gilron I","year":"2006","unstructured":"Gilron I, Watson CP, Cahill CM, Moulin DE. Neuropathic pain: a practical guide for the clinician. CMAJ. 2006, 175:265-75. 10.1503\/cmaj.060146","journal-title":"CMAJ"},{"key":"ref106","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.3795-08.2008","article-title":"Nociceptors are interleukin-1beta sensors","volume":"28","author":"Binshtok AM","year":"2008","unstructured":"Binshtok AM, Wang H, Zimmermann K, et al.. Nociceptors are interleukin-1beta sensors. J Neurosci. 2008, 28:14062-73. 10.1523\/JNEUROSCI.3795-08.2008","journal-title":"J Neurosci"},{"key":"ref107","doi-asserted-by":"publisher","DOI":"10.1126\/science.abd3072","article-title":"Neuropilin-1 is a host factor for SARS-CoV-2 infection","volume":"370","author":"Daly JL","year":"2020","unstructured":"Daly JL, Simonetti B, Klein K, et al.. Neuropilin-1 is a host factor for SARS-CoV-2 infection. Science. 2020, 370:861-5. 10.1126\/science.abd3072","journal-title":"Science"},{"key":"ref108","doi-asserted-by":"publisher","DOI":"10.3892\/mmr.2020.11510","article-title":"Neuropilin\u20111 as a new potential SARS\u2011CoV\u20112 infection mediator implicated in the neurologic features and central nervous system involvement of COVID\u201119","volume":"22","author":"Davies J","year":"2020","unstructured":"Davies J, Randeva HS, Chatha K, et al.. Neuropilin\u20111 as a new potential SARS\u2011CoV\u20112 infection mediator implicated in the neurologic features and central nervous system involvement of COVID\u201119. Mol Med Rep. 2020, 22:4221-6. 10.3892\/mmr.2020.11510","journal-title":"Mol Med Rep"},{"key":"ref109","doi-asserted-by":"publisher","DOI":"10.1186\/s12872-015-0124-z","article-title":"Endothelial cell control of thrombosis","volume":"15","author":"Yau JW","year":"2015","unstructured":"Yau JW, Teoh H, Verma S. Endothelial cell control of thrombosis. BMC Cardiovasc Disord. 2015, 15:130. 10.1186\/s12872-015-0124-z","journal-title":"BMC Cardiovasc Disord"},{"key":"ref110","doi-asserted-by":"publisher","DOI":"10.3390\/v13010029","article-title":"Endothelium infection and dysregulation by SARS-CoV-2: evidence and caveats in COVID-19","volume":"13","author":"Bernard I","year":"2020","unstructured":"Bernard I, Limonta D, Mahal LK, Hobman TC. Endothelium infection and dysregulation by SARS-CoV-2: evidence and caveats in COVID-19. Viruses. 2020, 13:10.3390\/v13010029","journal-title":"Viruses"},{"key":"ref111","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9051417","article-title":"Hypertension, thrombosis, kidney failure, and diabetes: is COVID-19 an endothelial disease? A comprehensive evaluation of clinical and basic evidence","volume":"9","author":"Sardu C","year":"2020","unstructured":"Sardu C, Gambardella J, Morelli MB, Wang X, Marfella R, Santulli G. Hypertension, thrombosis, kidney failure, and diabetes: is COVID-19 an endothelial disease? A comprehensive evaluation of clinical and basic evidence. J Clin Med. 2020, 9:1417. 10.3390\/jcm9051417","journal-title":"J Clin Med"},{"key":"ref112","doi-asserted-by":"publisher","DOI":"10.2337\/dc20-0723","article-title":"Outcomes in patients with hyperglycemia affected by COVID-19: can we do more on glycemic control?","volume":"43","author":"Sardu C","year":"2020","unstructured":"Sardu C, D'Onofrio N, Balestrieri ML, et al.. Outcomes in patients with hyperglycemia affected by COVID-19: can we do more on glycemic control?. Diabetes Care. 2020, 43:1408-15. 10.2337\/dc20-0723","journal-title":"Diabetes Care"},{"key":"ref113","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2020.117179","article-title":"Post-COVID 19 neurological syndrome (PCNS): a novel syndrome with challenges for the global neurology community","volume":"419","author":"Wijeratne T","year":"2020","unstructured":"Wijeratne T, Crewther S. Post-COVID 19 neurological syndrome (PCNS): a novel syndrome with challenges for the global neurology community. J Neurol Sci. 2020, 419:117179. 10.1016\/j.jns.2020.117179","journal-title":"J Neurol Sci"},{"key":"ref114","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(20)30221-0","article-title":"Neurological associations of COVID-19","volume":"19","author":"Ellul MA","year":"2020","unstructured":"Ellul MA, Benjamin L, Singh B, et al.. Neurological associations of COVID-19. Lancet Neurol. 2020, 19:767-83. 10.1016\/S1474-4422(20)30221-0","journal-title":"Lancet Neurol"},{"key":"ref115","doi-asserted-by":"publisher","DOI":"10.1097\/01.JAA.0000481401.21841.32","article-title":"Post-ICU syndrome: rescuing the undiagnosed","volume":"29","author":"Myers EA","year":"2016","unstructured":"Myers EA, Smith DA, Allen SR, Kaplan LJ. Post-ICU syndrome: rescuing the undiagnosed. JAAPA. 2016, 29:34-7. 10.1097\/01.JAA.0000481401.21841.32","journal-title":"JAAPA"},{"key":"ref116","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2019.04.021","article-title":"Chronic inflammatory demyelinating polyneuropathy as an autoimmune disease","volume":"102","author":"Rodr\u00edguez Y","year":"2019","unstructured":"Rodr\u00edguez Y, Vatti N, Ram\u00edrez-Santana C, et al.. Chronic inflammatory demyelinating polyneuropathy as an autoimmune disease. J Autoimmun. 2019, 102:8-37. 10.1016\/j.jaut.2019.04.021","journal-title":"J Autoimmun"},{"key":"ref117","doi-asserted-by":"publisher","DOI":"10.1016\/j.bja.2020.05.021","article-title":"Chronic pain after COVID-19: implications for rehabilitation","volume":"125","author":"Kemp HI","year":"2020","unstructured":"Kemp HI, Corner E, Colvin LA. Chronic pain after COVID-19: implications for rehabilitation. Br J Anaesth. 2020, 125:436-40. 10.1016\/j.bja.2020.05.021","journal-title":"Br J Anaesth"},{"key":"ref118","doi-asserted-by":"publisher","DOI":"10.1016\/j.bja.2019.03.025","article-title":"Chronic pain in critical care survivors: a narrative review","volume":"123","author":"Kemp HI","year":"2019","unstructured":"Kemp HI, Laycock H, Costello A, Brett SJ. Chronic pain in critical care survivors: a narrative review. Br J Anaesth. 2019, 123:e372-84. 10.1016\/j.bja.2019.03.025","journal-title":"Br J Anaesth"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/86853-neuropathic-pain-in-neurologic-disorders-a-narrative-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:45:59Z","timestamp":1707507959000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/86853-neuropathic-pain-in-neurologic-disorders-a-narrative-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,20]]},"references-count":118,"URL":"https:\/\/doi.org\/10.7759\/cureus.22419","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2,20]]}}}